ArticleCritical care (London, England)2026
Real-world longitudinal validation of high-income-country-derived sepsis endotypes in sub-Saharan Africa: a nested prospective multicenter study.
Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSub-Saharan Africa accounts for an estimated 40% of global sepsis-related deaths, with 30-day mortality exceeding 50% among hospitalized adults. While factors such as causative pathogens, comorbidities and delayed presentation contribute to mortality risk, the role of the host response remains poorly understood. In high income countries (HICs), transcriptomic endotypes have been linked to sepsis prognosis, highlighting distinct signatures. Assessing the applicability of these endotypes in low- and middle-income countries, particularly in sub-Saharan Africa where the sepsis burden is highest, is needed.
methodsAs part of the African Research Collaboration on Sepsis (ARCS) Cohort and the Cardiovascular Responses In Septic Patients (CRISP) studies, a subset of adult participants hospitalized with clinically suspected infection in Malawi and Uganda provided whole blood samples, collected longitudinally on days 0, 2/3 and 28, for RNA-sequencing. Sepsis was defined by a modified Sequential Organ Failure Assessment (mSOFA) score ≥ 2. Three sepsis messenger RNA endotypes [Sepsis Response Signature (SRS), Molecular Diagnosis and Risk Stratification of Sepsis (MARS) and Inflammopathic-Coagulopathic-Adaptive], previously derived in HIC settings, were validated for prognostic relevance among study participants.
resultsRNAseq was performed on a randomly selected subset of 278 samples belonging to 158 study participants, for whom HIV seropositivity was 51.3% and sepsis prevalence was 56.3% (mSOFA ≥ 2). The most commonly observed signatures over all timepoints were SRS2 (63.3%), Mars3 (31.2%) and Coagulopathic (41.7%), while SRS3 (16.5%), Mars4 (12.7%) and Adaptive (27.7%) were the least common. Participants classified as SRS1, Mars2 or Inflammopathic endotypes were associated with worse outcomes; when compared to the others pooled together, hazard ratios for 30-day mortality were significantly higher for the SRS1 (HR 2.81; 95% CI: 1.17–6.77), Mars2 (HR 3.11; 95% CI: 1.24–7.79) and Inflammopathic (HR 2.66; 95% CI: 1.09–6.52) signatures. Follow-up samples showed that the proportion of signatures associated with more adverse outcomes decreased, while the proportion of less severe ones increased, despite possible survivorship bias. Signatures associated with similar disease severity were strongly correlated between mRNA endotypes (p < 0.001; Cramer’s V > 0.4). Signature classification was not associated with HIV status.
conclusionsSepsis endotypes identified in HICs exhibit similar biological and clinical characteristics in sub-Saharan Africa. Longitudinal analysis revealed that the proportion of adverse endotype signatures decrease over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.